Ann: Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting, page-144

Of course an updated HerVaxx data set would be great for all to see.

it would be super important for everyone to understand if we don't actually see anything fresh from what was reported last November it means the Stable Disease patients at that point have not yet progressed in order to register a PFS or OS timeframe.

Which therefore has to add an additional 5 months of precious time to survival for these patients. A remarkable outcome.

If however all of the Chemo only control group have now progressed and a median PFS time is available for them, this could be reported and at least we will know the baseline whilst waiting for the HerVax cohort measure.